Eintrag weiter verarbeiten
Anti-MUC1 Antibodies and Ovarian Cancer Risk: Prospective Data from the Nurses' Health Studies
Gespeichert in:
| Zeitschriftentitel: | Cancer Epidemiology, Biomarkers & Prevention |
|---|---|
| Personen und Körperschaften: | , , , , , , |
| In: | Cancer Epidemiology, Biomarkers & Prevention, 19, 2010, 6, S. 1595-1601 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Association for Cancer Research (AACR)
|
| Schlagwörter: |
| author_facet |
Pinheiro, Simone P. Hankinson, Susan E. Tworoger, Shelley S. Rosner, Bernard A. McKolanis, John R. Finn, Olivera J. Cramer, Daniel W. Pinheiro, Simone P. Hankinson, Susan E. Tworoger, Shelley S. Rosner, Bernard A. McKolanis, John R. Finn, Olivera J. Cramer, Daniel W. |
|---|---|
| author |
Pinheiro, Simone P. Hankinson, Susan E. Tworoger, Shelley S. Rosner, Bernard A. McKolanis, John R. Finn, Olivera J. Cramer, Daniel W. |
| spellingShingle |
Pinheiro, Simone P. Hankinson, Susan E. Tworoger, Shelley S. Rosner, Bernard A. McKolanis, John R. Finn, Olivera J. Cramer, Daniel W. Cancer Epidemiology, Biomarkers & Prevention Anti-MUC1 Antibodies and Ovarian Cancer Risk: Prospective Data from the Nurses' Health Studies Oncology Epidemiology |
| author_sort |
pinheiro, simone p. |
| spelling |
Pinheiro, Simone P. Hankinson, Susan E. Tworoger, Shelley S. Rosner, Bernard A. McKolanis, John R. Finn, Olivera J. Cramer, Daniel W. 1055-9965 1538-7755 American Association for Cancer Research (AACR) Oncology Epidemiology http://dx.doi.org/10.1158/1055-9965.epi-10-0068 <jats:title>Abstract</jats:title> <jats:p>Background: The surface epithelial glycoprotein MUC1 becomes overexpressed and hypoglycosylated in adenocarcinomas; similar changes occur during nonmalignant inflammatory events. Antibodies developed against tumor-like MUC1 in response to such events could be one way through which ovarian cancer risk factors operate.</jats:p> <jats:p>Methods: We evaluated the association between anti-MUC1 antibodies and risk of ovarian cancer in a prospective nested case-control study in the Nurses' Health Studies. We used an ELISA to measure plasma anti-MUC1 antibodies in 117 ovarian cancer cases collected at least 3 years before diagnosis and 339 matched controls.</jats:p> <jats:p>Results: In controls, younger women (P-trend = 0.03), those with a tubal ligation (P = 0.03), and those with fewer ovulatory cycles (P-trend = 0.04) had higher antibody levels. In cases, women with late-stage disease (P = 0.04) and those whose specimen was &gt;11 years remote from diagnosis (P = 0.01) had higher antibody levels. Overall, increasing anti-MUC1 antibody levels were associated with a nonsignificant trend for lower risk for ovarian cancer, but there was highly significant heterogeneity by age (P-heterogeneity = 0.005). In women &lt;64 years, the antibody level in quartiles 2 to 4 versus quartile 1 were associated with reduced risk (relative risk = 0.53; 95% confidence interval, 0.31-0.93; P-trend = 0.03), whereas in women ≥64 years, the corresponding relative risk was 2.11 (95% confidence interval, 0.73-6.04); P-trend = 0.05).</jats:p> <jats:p>Conclusion: Anti-MUC1 antibodies evaluated several years before diagnosis may be associated with lower risk of subsequent ovarian cancer in women &lt;64 years old at assessment.</jats:p> <jats:p>Impact: Key elements of an “immune model” to explain ovarian cancer risk factors are confirmed and should be evaluated in larger prospective studies. Cancer Epidemiol Biomarkers Prev; 19(6); 1595–601. ©2010 AACR.</jats:p> Anti-MUC1 Antibodies and Ovarian Cancer Risk: Prospective Data from the Nurses' Health Studies Cancer Epidemiology, Biomarkers & Prevention |
| doi_str_mv |
10.1158/1055-9965.epi-10-0068 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xMDU1LTk5NjUuZXBpLTEwLTAwNjg |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xMDU1LTk5NjUuZXBpLTEwLTAwNjg |
| institution |
DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 |
| imprint |
American Association for Cancer Research (AACR), 2010 |
| imprint_str_mv |
American Association for Cancer Research (AACR), 2010 |
| issn |
1055-9965 1538-7755 |
| issn_str_mv |
1055-9965 1538-7755 |
| language |
English |
| mega_collection |
American Association for Cancer Research (AACR) (CrossRef) |
| match_str |
pinheiro2010antimuc1antibodiesandovariancancerriskprospectivedatafromthenurseshealthstudies |
| publishDateSort |
2010 |
| publisher |
American Association for Cancer Research (AACR) |
| recordtype |
ai |
| record_format |
ai |
| series |
Cancer Epidemiology, Biomarkers & Prevention |
| source_id |
49 |
| title |
Anti-MUC1 Antibodies and Ovarian Cancer Risk: Prospective Data from the Nurses' Health Studies |
| title_unstemmed |
Anti-MUC1 Antibodies and Ovarian Cancer Risk: Prospective Data from the Nurses' Health Studies |
| title_full |
Anti-MUC1 Antibodies and Ovarian Cancer Risk: Prospective Data from the Nurses' Health Studies |
| title_fullStr |
Anti-MUC1 Antibodies and Ovarian Cancer Risk: Prospective Data from the Nurses' Health Studies |
| title_full_unstemmed |
Anti-MUC1 Antibodies and Ovarian Cancer Risk: Prospective Data from the Nurses' Health Studies |
| title_short |
Anti-MUC1 Antibodies and Ovarian Cancer Risk: Prospective Data from the Nurses' Health Studies |
| title_sort |
anti-muc1 antibodies and ovarian cancer risk: prospective data from the nurses' health studies |
| topic |
Oncology Epidemiology |
| url |
http://dx.doi.org/10.1158/1055-9965.epi-10-0068 |
| publishDate |
2010 |
| physical |
1595-1601 |
| description |
<jats:title>Abstract</jats:title>
<jats:p>Background: The surface epithelial glycoprotein MUC1 becomes overexpressed and hypoglycosylated in adenocarcinomas; similar changes occur during nonmalignant inflammatory events. Antibodies developed against tumor-like MUC1 in response to such events could be one way through which ovarian cancer risk factors operate.</jats:p>
<jats:p>Methods: We evaluated the association between anti-MUC1 antibodies and risk of ovarian cancer in a prospective nested case-control study in the Nurses' Health Studies. We used an ELISA to measure plasma anti-MUC1 antibodies in 117 ovarian cancer cases collected at least 3 years before diagnosis and 339 matched controls.</jats:p>
<jats:p>Results: In controls, younger women (P-trend = 0.03), those with a tubal ligation (P = 0.03), and those with fewer ovulatory cycles (P-trend = 0.04) had higher antibody levels. In cases, women with late-stage disease (P = 0.04) and those whose specimen was &gt;11 years remote from diagnosis (P = 0.01) had higher antibody levels. Overall, increasing anti-MUC1 antibody levels were associated with a nonsignificant trend for lower risk for ovarian cancer, but there was highly significant heterogeneity by age (P-heterogeneity = 0.005). In women &lt;64 years, the antibody level in quartiles 2 to 4 versus quartile 1 were associated with reduced risk (relative risk = 0.53; 95% confidence interval, 0.31-0.93; P-trend = 0.03), whereas in women ≥64 years, the corresponding relative risk was 2.11 (95% confidence interval, 0.73-6.04); P-trend = 0.05).</jats:p>
<jats:p>Conclusion: Anti-MUC1 antibodies evaluated several years before diagnosis may be associated with lower risk of subsequent ovarian cancer in women &lt;64 years old at assessment.</jats:p>
<jats:p>Impact: Key elements of an “immune model” to explain ovarian cancer risk factors are confirmed and should be evaluated in larger prospective studies. Cancer Epidemiol Biomarkers Prev; 19(6); 1595–601. ©2010 AACR.</jats:p> |
| container_issue |
6 |
| container_start_page |
1595 |
| container_title |
Cancer Epidemiology, Biomarkers & Prevention |
| container_volume |
19 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792335199337447425 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T14:39:09.33Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Anti-MUC1+Antibodies+and+Ovarian+Cancer+Risk%3A+Prospective+Data+from+the+Nurses%27+Health+Studies&rft.date=2010-06-01&genre=article&issn=1538-7755&volume=19&issue=6&spage=1595&epage=1601&pages=1595-1601&jtitle=Cancer+Epidemiology%2C+Biomarkers+%26+Prevention&atitle=Anti-MUC1+Antibodies+and+Ovarian+Cancer+Risk%3A+Prospective+Data+from+the+Nurses%27+Health+Studies&aulast=Cramer&aufirst=Daniel+W.&rft_id=info%3Adoi%2F10.1158%2F1055-9965.epi-10-0068&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792335199337447425 |
| author | Pinheiro, Simone P., Hankinson, Susan E., Tworoger, Shelley S., Rosner, Bernard A., McKolanis, John R., Finn, Olivera J., Cramer, Daniel W. |
| author_facet | Pinheiro, Simone P., Hankinson, Susan E., Tworoger, Shelley S., Rosner, Bernard A., McKolanis, John R., Finn, Olivera J., Cramer, Daniel W., Pinheiro, Simone P., Hankinson, Susan E., Tworoger, Shelley S., Rosner, Bernard A., McKolanis, John R., Finn, Olivera J., Cramer, Daniel W. |
| author_sort | pinheiro, simone p. |
| container_issue | 6 |
| container_start_page | 1595 |
| container_title | Cancer Epidemiology, Biomarkers & Prevention |
| container_volume | 19 |
| description | <jats:title>Abstract</jats:title> <jats:p>Background: The surface epithelial glycoprotein MUC1 becomes overexpressed and hypoglycosylated in adenocarcinomas; similar changes occur during nonmalignant inflammatory events. Antibodies developed against tumor-like MUC1 in response to such events could be one way through which ovarian cancer risk factors operate.</jats:p> <jats:p>Methods: We evaluated the association between anti-MUC1 antibodies and risk of ovarian cancer in a prospective nested case-control study in the Nurses' Health Studies. We used an ELISA to measure plasma anti-MUC1 antibodies in 117 ovarian cancer cases collected at least 3 years before diagnosis and 339 matched controls.</jats:p> <jats:p>Results: In controls, younger women (P-trend = 0.03), those with a tubal ligation (P = 0.03), and those with fewer ovulatory cycles (P-trend = 0.04) had higher antibody levels. In cases, women with late-stage disease (P = 0.04) and those whose specimen was &gt;11 years remote from diagnosis (P = 0.01) had higher antibody levels. Overall, increasing anti-MUC1 antibody levels were associated with a nonsignificant trend for lower risk for ovarian cancer, but there was highly significant heterogeneity by age (P-heterogeneity = 0.005). In women &lt;64 years, the antibody level in quartiles 2 to 4 versus quartile 1 were associated with reduced risk (relative risk = 0.53; 95% confidence interval, 0.31-0.93; P-trend = 0.03), whereas in women ≥64 years, the corresponding relative risk was 2.11 (95% confidence interval, 0.73-6.04); P-trend = 0.05).</jats:p> <jats:p>Conclusion: Anti-MUC1 antibodies evaluated several years before diagnosis may be associated with lower risk of subsequent ovarian cancer in women &lt;64 years old at assessment.</jats:p> <jats:p>Impact: Key elements of an “immune model” to explain ovarian cancer risk factors are confirmed and should be evaluated in larger prospective studies. Cancer Epidemiol Biomarkers Prev; 19(6); 1595–601. ©2010 AACR.</jats:p> |
| doi_str_mv | 10.1158/1055-9965.epi-10-0068 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xMDU1LTk5NjUuZXBpLTEwLTAwNjg |
| imprint | American Association for Cancer Research (AACR), 2010 |
| imprint_str_mv | American Association for Cancer Research (AACR), 2010 |
| institution | DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4 |
| issn | 1055-9965, 1538-7755 |
| issn_str_mv | 1055-9965, 1538-7755 |
| language | English |
| last_indexed | 2024-03-01T14:39:09.33Z |
| match_str | pinheiro2010antimuc1antibodiesandovariancancerriskprospectivedatafromthenurseshealthstudies |
| mega_collection | American Association for Cancer Research (AACR) (CrossRef) |
| physical | 1595-1601 |
| publishDate | 2010 |
| publishDateSort | 2010 |
| publisher | American Association for Cancer Research (AACR) |
| record_format | ai |
| recordtype | ai |
| series | Cancer Epidemiology, Biomarkers & Prevention |
| source_id | 49 |
| spelling | Pinheiro, Simone P. Hankinson, Susan E. Tworoger, Shelley S. Rosner, Bernard A. McKolanis, John R. Finn, Olivera J. Cramer, Daniel W. 1055-9965 1538-7755 American Association for Cancer Research (AACR) Oncology Epidemiology http://dx.doi.org/10.1158/1055-9965.epi-10-0068 <jats:title>Abstract</jats:title> <jats:p>Background: The surface epithelial glycoprotein MUC1 becomes overexpressed and hypoglycosylated in adenocarcinomas; similar changes occur during nonmalignant inflammatory events. Antibodies developed against tumor-like MUC1 in response to such events could be one way through which ovarian cancer risk factors operate.</jats:p> <jats:p>Methods: We evaluated the association between anti-MUC1 antibodies and risk of ovarian cancer in a prospective nested case-control study in the Nurses' Health Studies. We used an ELISA to measure plasma anti-MUC1 antibodies in 117 ovarian cancer cases collected at least 3 years before diagnosis and 339 matched controls.</jats:p> <jats:p>Results: In controls, younger women (P-trend = 0.03), those with a tubal ligation (P = 0.03), and those with fewer ovulatory cycles (P-trend = 0.04) had higher antibody levels. In cases, women with late-stage disease (P = 0.04) and those whose specimen was &gt;11 years remote from diagnosis (P = 0.01) had higher antibody levels. Overall, increasing anti-MUC1 antibody levels were associated with a nonsignificant trend for lower risk for ovarian cancer, but there was highly significant heterogeneity by age (P-heterogeneity = 0.005). In women &lt;64 years, the antibody level in quartiles 2 to 4 versus quartile 1 were associated with reduced risk (relative risk = 0.53; 95% confidence interval, 0.31-0.93; P-trend = 0.03), whereas in women ≥64 years, the corresponding relative risk was 2.11 (95% confidence interval, 0.73-6.04); P-trend = 0.05).</jats:p> <jats:p>Conclusion: Anti-MUC1 antibodies evaluated several years before diagnosis may be associated with lower risk of subsequent ovarian cancer in women &lt;64 years old at assessment.</jats:p> <jats:p>Impact: Key elements of an “immune model” to explain ovarian cancer risk factors are confirmed and should be evaluated in larger prospective studies. Cancer Epidemiol Biomarkers Prev; 19(6); 1595–601. ©2010 AACR.</jats:p> Anti-MUC1 Antibodies and Ovarian Cancer Risk: Prospective Data from the Nurses' Health Studies Cancer Epidemiology, Biomarkers & Prevention |
| spellingShingle | Pinheiro, Simone P., Hankinson, Susan E., Tworoger, Shelley S., Rosner, Bernard A., McKolanis, John R., Finn, Olivera J., Cramer, Daniel W., Cancer Epidemiology, Biomarkers & Prevention, Anti-MUC1 Antibodies and Ovarian Cancer Risk: Prospective Data from the Nurses' Health Studies, Oncology, Epidemiology |
| title | Anti-MUC1 Antibodies and Ovarian Cancer Risk: Prospective Data from the Nurses' Health Studies |
| title_full | Anti-MUC1 Antibodies and Ovarian Cancer Risk: Prospective Data from the Nurses' Health Studies |
| title_fullStr | Anti-MUC1 Antibodies and Ovarian Cancer Risk: Prospective Data from the Nurses' Health Studies |
| title_full_unstemmed | Anti-MUC1 Antibodies and Ovarian Cancer Risk: Prospective Data from the Nurses' Health Studies |
| title_short | Anti-MUC1 Antibodies and Ovarian Cancer Risk: Prospective Data from the Nurses' Health Studies |
| title_sort | anti-muc1 antibodies and ovarian cancer risk: prospective data from the nurses' health studies |
| title_unstemmed | Anti-MUC1 Antibodies and Ovarian Cancer Risk: Prospective Data from the Nurses' Health Studies |
| topic | Oncology, Epidemiology |
| url | http://dx.doi.org/10.1158/1055-9965.epi-10-0068 |